Φορτώνει......
Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases
Brain metastases occur in up to 25–55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in most patients. Temozolomide (TMZ) is known to penetrate the blood–brain barrier and is US FDA appro...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Future Oncol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Future Medicine Ltd
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7270957/ https://ncbi.nlm.nih.gov/pubmed/32270710 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2020-0094 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|